Loading...
Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data
PURPOSE: Second-line treatment with ramucirumab-paclitaxel has demonstrated statistically significant and clinically meaningful survival outcomes compared to paclitaxel-alone in patients with advanced gastric cancer (HR=0.807, 95% CI 0.678–0.962; P=0.017). Post hoc, exploratory analyses of RAINBOW p...
Na minha lista:
| Udgivet i: | Cancer Manag Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6433106/ https://ncbi.nlm.nih.gov/pubmed/30962715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S193739 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|